Slide 1: Orion Interim Report January–September 2015
Orion Interim Report January─September 2015 27 October 2015 Timo Lappalainen President & CEO
Slide 2: Forward-looking statements disclaimer
This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strat
Slide 3: Product sales developed well
Product sales developed well • Net sales and operating profit at similar level to comparative period • Product sales developed well and margin level improved • Specialty Products maintained strong growth • No material impact yet from extension of generic competition to Stalevo outside Germany • In R
Slide 4: Net sales and operating profit
Net sales and operating profit Basic earnings per Laimentamaton Cash flow perrahavirta share Net sales, Operating profit, Osakekohtainen EUR million EUR million osakekohtainen tulos, € share, EUR before financial ennen items, rahoituseriä, € EUR 760 754 217 216 1.21 1.34 1.20 1.11 Q1-Q3/2014 Q1-Q3/2
Slide 5: Breakdown of net sales
Breakdown of net sales Group’s net sales in Q1─Q3/2015 were EUR 754 million By business division By market area 5% 4% 14% 6% 32% 31% 8% 8% 45% 31% 16% Proprietary Products Specialty Products Animal Health Finland Scandinavia Fermion Other Europe North America Contract manufacturing & other Orion Dia
Slide 6: Business Reviews
Business Reviews
Slide 7: Pharmaceuticals business
Pharmaceuticals business Q1─Q3/2014 Q1─Q3/2015 Net sales split 721 714 EUR million Q1─Q3 Q1─Q3 /2015 /2014 Change % Proprietary Products 244 285 -14% Specialty Products 339 310 +9% Animal Health 59 50 +18% 219 217 Fermion 43 46 -5% Contract manufacturing & other 28 29 -5% • Net sales excluding brand
Slide 8: Best-selling pharmaceuticals Q1–Q3/2015
Best-selling pharmaceuticals Q1─Q3/2015 2014 Net sales, EUR million Stalevo®, Comtess® & Comtan® (Parkinson’s disease) -18% -14% 112 169 Simdax® (acute decompensated heart failure) +2% +8% 37 47 Easyhaler® product family (asthma, COPD) +22% +49% 37 35 dexdor® (intensive care sedative) +39% +30% 32 3
Slide 9: Orion clear market leader in Finland
Orion clear market leader in Finland Finnish human pharmaceuticals Finland’s biggest pharmaceutical market in January─September 2015 companies in Q1─Q3/2015 EUR million • Wholesale EUR 1,620 million (+3%) 250 Orion in Finnish human 200 195 pharmaceuticals market • Sales growth +7% 150 • Orion clear
Slide 10: Review of Parkinson's drugs markets
Review of Parkinson’s drugs markets Overall markets for Parkinson’s drugs Market shares of Orion’s MAT6/ MAT6/ USD / EUR million MAT6/2015 MAT6/2014 Change % branded Parkinson’s drugs 2015 2014 USA USD 821 811 +1% Finland 2) 17% 22% EU TOP 5 1) EUR 958 994 -4% Sweden 2) 12% 14% Japan EUR 543 491 +11
Slide 11: dexdor intensive care sedative
dexdor® intensive care sedative European sedative market MAT6/2015* Dexdor sales Total market value EUR 515 million (+3%) 12 13% 10 6% 8 15% 6 66% 4 2 0 Propofol EUR 341 million (+1%) Midazolam EUR 76 million (-2%) Dexmedetomidine EUR 32 million (+34%) Remifentanil EUR 65 million (+9%) Dexdor sales,
Slide 12: Key clinical pharmaceutical development projects 1/2
Key clinical pharmaceutical development projects 1/2 Project Indication PHASE Registration Bufomix Easyhaler® (budesonide-formoterol) 1) Asthma, COPD I II III Easyhaler® salmeterol-fluticasone Asthma, COPD I II III ODM-201 (androgen receptor inhibitor) 2) Prostate cancer I II III Low Cardiac Output
Slide 13: Key clinical pharmaceutical development projects 2/2
Key clinical pharmaceutical development projects 2/2 Project Indication PHASE Registration ODM-104 (more effective COMT inhibitor) Parkinson’s disease I ODM-203 (targeted FGFR+VEGFR inhibitor) Solid tumours I ODM-204 (CYP17 enzyme and androgen receptor inhibitor) Prostate cancer I ODM-108 (negative
Slide 14: Diagnostics business
Diagnostics business Q1─Q3/2014 Q1─Q3/2015 • Operating profit growth mainly due to favourable margin 42 43 structure of sales from portfolio and exchange rate changes • QuikRead® tests remained the 4.9 6.8 main product • Launching of the first Orion Net sales, EUR Operating profit, GenRead® test sys
Slide 15: Outlook for 2015 (updated July 2015)
Outlook for 2015 (updated on 9 July 2015) Net sales are estimated to be at similar level to 2014 Net sales (net sales were EUR 1,015 million in 2014). Operating profit Operating profit is estimated to exceed EUR 260 million. The Group’s capital expenditure will be about EUR 50 Group’s capital millio
Slide 16: Orion Calendar 2016
Orion Calendar 2016 Financial Statement Release for 2015 Tue 2 Feb 2016 Annual General Meeting 2016 planned to be held on Tue 22 Mar 2016 Interim Report January─March 2016 Wed 27 Apr 2016 Interim Report January─June 2016 Tue 19 Jul 2016 Interim Report January─September 2016 Tue 25 Oct 2016 The Finan
Slide 17: Orion Building well-being
GRION Building well-being
Slide 18: Orion's financial objectives
Orion’s financial objectives Increasing net sales. Achievement of this objective requires continuous investment in development of the product portfolio. > Maintaining profitability at a good level. The aim is operating profit that exceeds 20% of net sales. ≥ Keeping the equity ratio at least 50%.
Slide 19: Key figures by quarter
Key figures by quarter EUR million Net sales EUR million Operating profit 1,200 300 1,000 250 60 59 55 66 254 273 255 800 236 Q4 200 65 Q4 76 64 59 67 600 246 237 238 239 Q3 150 Q3 211 Q2 65 74 Q2 65 61 86 400 277 255 100 227 233 248 Q1 Q1 200 50 93 83 79 74 67 244 247 249 245 260 0 0 11 12 13 14 15
Slide 20: Key figures for 2011–Q3/2015
Key figures for 2011─Q3/2015 Orion’s key figures 2011 2012 2013 2014 Q1─Q3/2015 Q1─Q3/2014 Change % Net sales, EUR million 917.9 980.4 1,006.9 1,015.3 754.0 760.0 -0.8% Operating profit, EUR million 282.9 278.3 267.7 272.4 215.6 217.2 -0.7% Profit before taxes, EUR million 282.0 276.6 264.0 267.8 21
Slide 21: Income Statement 2011–Q3/2015
Income Statement 2011─Q3/2015 Formation of profits, EUR million 2011 2012 2013 2014 Q1─Q3/2015 Q1─Q3/2014 Change % Net sales 917.9 980.4 1,006.9 1,015.3 754.0 760.0 -0.8% Cost of goods sold -305.1 -350.8 -393.5 -401.7 -291.2 -295.5 -1.4% Gross profit 612.8 629.6 613.4 613.6 462.8 464.5 -0.4% Other o
Slide 22: Product protection situation of key products
Product protection situation of key products Key patents or data protection expire Molecule Product Indication Europe USA Japan Stalevo®, November 2012 January Entacapone Parkinson’s disease October 2013 Comtess® and Comtan® October 2013 1) 2015 2) Acute Levosimendan Simdax® decompensated September
Slide 23: Dividend distribution policy
Dividend distribution policy Orion’s dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives. Dividend distribution history EUR 1.60 100% 0.12 EUR 1.40 0.06 95% EUR 1.20 0.10 90%
Slide 24: Slide 24